Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: A retrospective analysis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 17, Issue 8, 2002, Pages 882-888

  Colle, Isabelle ^a,b,c   Durand, François ^a,b   Pessione, Fabienne ^b   Rassiat, Emmanuel ^a,b   Bernuau, Jacques ^a,b   Barrière, Eric ^a,b   Lebrec, Didier ^a,b   Valla, Dominique Charles ^a,b   Moreau, Richard ^a,b  

^a INSERM   (France)

^b BEAUJON HOSPITAL   (France)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Cirrhosis; Prognosis; Terlipressin; Type 1 hepatorenal syndrome

Indexed keywords

ALBUMIN; ANTIBIOTIC AGENT; CREATININE; GLYPRESSINE; POLYGELINE; TERLIPRESSIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEATH; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; FACTORIAL ANALYSIS; FEMALE; HEPATORENAL SYNDROME; HUMAN; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MEDICAL RECORD; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SCORING SYSTEM; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0036381036     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2002.02816.x     Document Type: Article

References (19)

1. Laffi G, La Villa G, Gentilini P. Pathogenesis and management of the hepatorenal syndrome. Semin. Liver Dis. 1994; 14: 71-81.
2. Arroyo V, Ginès P, Gerbes AL et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996; 23: 164-76.
3. Bataller R, Ginès P, Guevara M, Arroyo V. Hepatorenal syndrome. Semin. Liver Dis. 1997; 17: 233-47.
4. Lenz K, Hortnagel H, Druml W et al. Ornipressin in the treatment of functional renal failure in decompensated cirrhosis. Effects on renal hemodynamics and atrial natriuretic factor. Gastroenterology 1991; 101: 1060-7.
5. Guevara M, Ginès P, Fernandez-Esparrach G et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998; 27: 35-41.
6. Hadengue A, Gadano A, Moreau R. et al. Beneficial effects of the two-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J. Hepatol. 1998; 29: 565-70.
7. Gülberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamin. Hepatology 1999; 30: 870-5.
8. Uriz J, Ginès P, Cardenas A et al. Terlipressin plus albumin infusion: An effective and safe therapy of hepatorenal syndrome. J. Hepatol. 2000; 33: 33-48.
9. Bonnard P, Bernard B, Halimi C et al. Effect of terlipressin (Glypressine®) on hepatorenal syndrome (HRS) in cirrhotic patients: Results of a pilot study (Abstract). Gastroenterology 1998; 114: A1214.
10. Le Moine O, Mulkay JP, Bourgeois N, Adler M, Devière J. Longterm terlipressin administration improves renal function in cirrhotic patients with hepatorenal syndrome (HRS): A pilot study (Abstract). Gastroenterology 1999; 116: A1258-9.
11. Mulkay JP, Louis H, Donckier V et al. Longterm terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: A pilot study. Acta Gastroenterol. Belg. 2001; 64: 15-19.
12. Gines P, Ortega R, Uriz J et al. Effects of terlipressin administration with and without albumin in hepatorenal syndrome. A phase II study. Hepatology 2001; 34 (Part 2): P186A.
13. Ginès A, Escorsell A, Ginès P et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105: 229-36.
14. Moreau R, Durand F, Poynard T et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: A retrospective multicenter study. Gastroenterology 2002; 122: 923-30.
15. Guarner C, Soriano G. Spontaneous bacterial peritonitis. Semin. Liver Dis. 1997; 17: 203-16.
16. Fevery J, Van Cutsem E, Nevens F, Van Steenbergen W, Verberckmoes R, De Groote J. Reversal of hepatorenal syndrome in four patients by peroral misoprostol (prostaglandin E1 analogue) and albumin administration. J. Hepatol. 1990; 11: 153-8.
17. Angeli P, Volpin R, Gerunda G et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29: 1690-7.
18. Holt S, Goodier D, Marley R et al. Improvement in renal function in hepatorenal syndrome with N-acetylcycteine. Lancet 1999; 353: 294-5.
19. Gadano A, Moreau R, Vachiery F et al. Natriuretic response to the combination of atrial natriuretic peptide and terlipressin in patients with cirrhosis and refractory ascites. J. Hepatol. 1997; 26: 1229-34.